We are contrasting Intec Pharma Ltd. (NASDAQ:NTEC) and Aimmune Therapeutics Inc. (NASDAQ:AIMT) on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another.
Table 1 shows the top-line revenue, earnings per share and valuation for Intec Pharma Ltd. and Aimmune Therapeutics Inc.
Table 2 represents Intec Pharma Ltd. (NASDAQ:NTEC) and Aimmune Therapeutics Inc. (NASDAQ:AIMT)’s return on assets, return on equity and net margins.
Insider Institutional Ownership
The shares of both Intec Pharma Ltd. and Aimmune Therapeutics Inc. are owned by institutional investors at 40.23% and 84.8% respectively. 16.08% are Intec Pharma Ltd.’s share owned by insiders. Insiders Comparatively, owned 0.4% of Aimmune Therapeutics Inc. shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.